Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Peptomyc S L is currently addressing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. The portfolio is divided between 2 distinct examiners, which prevents a single point of failure in the prosecution process. Additionally, the 2 pending office actions are situated in 2 distinct art units, reflecting the specialized nature of the biotechnology involved.
The busiest examiner for the entity is HOLTZMAN, KATHERINE ANN, who is managing 1 pending office action. This 1 pending office action is one of the 2 pending office actions that the company must resolve. Because the 2 distinct examiners operate within 2 distinct art units, the legal team must adapt to different examination cultures within the Biotechnology & Pharmaceuticals field.
With 2 pending office actions and 2 distinct examiners, the company has a distributed risk profile. HOLTZMAN, KATHERINE ANN handles 1 pending office action, while the other is reviewed in a different art unit. Success in the Biotechnology & Pharmaceuticals area will depend on navigating the specific technical hurdles presented by these 2 distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIG, KAILA ANGELIQUE | 1 | 33.8% | +25.2% |
| HOLTZMAN, KATHERINE ANN | 1 | 64.8% | +59.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17593403 | METHODS FOR THE DIAGNOSIS OF LUNG CANCER | CRAIG, KAILA ANGELIQUE | — |
| 17593408 | COMBINATION THERAPY WITH OMOMYC AND AN ANTIBODY BINDING PD-1 OR CTLA-4 FOR THE TREATMENT OF CANCER | HOLTZMAN, KATHERINE ANN | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17593403 | METHODS FOR THE DIAGNOSIS OF LUNG CANCER | CRAIG, KAILA ANGELIQUE | 1618 | §103 | Non-Final OA | — | Pending | Sep 17, 2021 |
| 17593408 | COMBINATION THERAPY WITH OMOMYC AND AN ANTIBODY BINDING PD-1 OR CTLA-4 FOR THE TREATMENT OF CANCER | HOLTZMAN, KATHERINE ANN | 1646 | §103DP | Non-Final OA | — | Pending | Sep 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPeptomyc S L has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kaila Angelique Craig has the most, with 1 of Peptomyc S L's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
